WNT5A and neoplasm: Tumor-derived factors, such as TGF-β and prostaglandin E2 (PGE2), alter pDC functionality by inhibiting their ability to produce type I IFN [66], and tumor cells expressing Wnt5a inhibit pDC activation and IFN-α secretion [67].